Abstract
OINV is a common pharmacologic side effect of opioids which patients often describe as more annoying than pain. CL-108, consisting of hydrocodone 7.5mg/ acetaminophen 325mg (HC/APAP) with rapid-release promethazine 12.5mg, is an analgesic being developed for the relief of moderate-to-severe pain and the prevention of OINV. An oral surgery study1 demonstrated the efficacy of CL-108 over 24 hours for pain compared to placebo and for OINV compared to HC/APAP (both p<0.001). To study CL-108 over 48 hours, a randomized, double-blind, phase III trial evaluated pain intensity reduction by CL-108 compared to placebo and the incidence of OINV compared to HC/APAP in patients following orthopedic surgery. To improve assay sensitivity, the study population was enriched by identifying patients with a history suggestive of being likely to develop nausea. After undergoing primary unilateral first metatarsal bunionectomy, 552 patients rated pain intensity on a categorical scale. If they had moderate or severe pain confirmed on a 0-10 numerical pain intensity rating scale (PI-NRS) patients were randomized to CL-108, HC/APAP, or placebo under double-blind conditions. They used the PI-NRS at regular intervals over 48 hours while documenting the presence, severity, and frequency of nausea, retching, and vomiting. Patients remedicated every 4-6 hours and took antiemetic and supplementary (rescue) analgesic medications as needed. The co-primary endpoints were SPID48 (for analgesia) and a composite OINV prevention endpoint (no vomiting or use of antiemetic over 48 hours). Patients who used CL-108 had significant pain relief compared to placebo and 74% reduction in the risk of developing OINV relative to patients who used HC/APAP (both p<0.001), with NNT of 4. There were no unexpected or serious side effects. We conclude that CL-108 is a safe and effective analgesic for moderate-to-severe pain and the prevention of OINV. (1. Schachtel, B J Pain. 2014.) Sponsored by Charleston Laboratories and Daiichi Sankyo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.